- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
Opinion
Video
Practice Pearls for Optimizing the Management of Hand and Foot Atopic Dermatitis
Author(s):
Dr. Alexandra Golant shares invaluable practice pearls for optimizing the management of hand and foot atopic dermatitis with the use of systemic treatments.
This is a video synopsis of a discussion involving Alexandra Golant, MD, Assistant Professor at the Icahn School of Medicine at Mount Sinai, focusing on key considerations for managing hand and foot atopic dermatitis (AD).
Dr. Golant emphasizes the importance of recognizing the impact of hand and foot involvement in AD, describing it as a condition with low body surface area but high impact on quality of life. She suggests evaluating patients based on treatment goals and quality of life impact to determine the need for systemic therapy.
Highlighting the effectiveness and safety of systemic treatment options, particularly biologics like dupilumab, Dr. Golant stresses the rapid onset of action and absence of significant adverse effects or immunosuppression. Recent data reaffirms the efficacy and safety of dupilumab for treating AD on the hands and feet, further supporting its use in these high-impact areas.
Dr. Golant's clinical approach involves identifying patients with hand and foot involvement and considering systemic therapy as appropriate, irrespective of body surface area. By addressing the substantial impact of AD on patients' confidence, work, and social interactions, systemic treatments aim to improve quality of life, alleviate itching, and empower patients to regain control over their lives despite the challenges posed by AD.
Video synopsis is AI-generated and reviewed by Dermatology Times®editorial staff.
